10x Genomics (NASDAQ:TXG) Posts Quarterly Earnings Results, Beats Expectations By $0.63 EPS

Key Points

• 10x Genomics reported an earnings per share (EPS) of $0.28, exceeding the consensus estimate of ($0.35) by $0.63.
• The company's revenue for the quarter was $172.91 million, surpassing analyst expectations of $139.36 million, and showed a 12.9% year-over-year increase.
• Insider trading activity included CEO Serge Saxonov selling 9,343 shares at an average price of $8.30, decreasing his ownership by 0.85%.

10x Genomics (NASDAQ:TXG - Get Free Report) released its earnings results on Thursday. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.63, Zacks reports. The company had revenue of $172.91 million during the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 13.15%. The firm's quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.32) EPS. 10x Genomics updated its Q3 2025 guidance to EPS.

10x Genomics Price Performance

Shares of NASDAQ TXG traded down $0.51 during midday trading on Friday, reaching $12.29. 4,792,434 shares of the stock traded hands, compared to its average volume of 3,030,776. The stock has a market capitalization of $1.51 billion, a PE ratio of -17.56 and a beta of 2.03. 10x Genomics has a one year low of $6.78 and a one year high of $24.76. The company's 50 day moving average is $11.91 and its 200 day moving average is $10.80.

Insider Activity

In other news, CEO Serge Saxonov sold 9,343 shares of 10x Genomics stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $8.30, for a total transaction of $77,546.90. Following the completion of the sale, the chief executive officer directly owned 1,083,625 shares in the company, valued at approximately $8,994,087.50. This trade represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 7,485 shares of 10x Genomics stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $8.30, for a total value of $62,125.50. Following the sale, the insider owned 448,374 shares of the company's stock, valued at approximately $3,721,504.20. This trade represents a 1.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,872 shares of company stock worth $173,238. 9.39% of the stock is currently owned by insiders.

Institutional Trading of 10x Genomics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its stake in shares of 10x Genomics by 163.5% during the first quarter. Goldman Sachs Group Inc. now owns 645,366 shares of the company's stock valued at $5,634,000 after buying an additional 400,430 shares during the period. Royal Bank of Canada increased its stake in shares of 10x Genomics by 806.4% during the first quarter. Royal Bank of Canada now owns 182,836 shares of the company's stock valued at $1,597,000 after buying an additional 162,665 shares during the period. Finally, Focus Partners Wealth purchased a new position in shares of 10x Genomics during the first quarter valued at $92,000. 84.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on TXG. Stephens reissued an "overweight" rating and issued a $14.00 target price on shares of 10x Genomics in a report on Thursday, May 15th. Barclays increased their target price on shares of 10x Genomics from $13.00 to $15.00 and gave the stock an "overweight" rating in a report on Friday. Bank of America increased their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Thursday, June 26th. Canaccord Genuity Group reduced their target price on shares of 10x Genomics from $18.00 to $15.00 and set a "buy" rating for the company in a report on Monday, May 12th. Finally, The Goldman Sachs Group reduced their target price on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating for the company in a report on Monday, May 12th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, 10x Genomics currently has a consensus rating of "Hold" and a consensus target price of $13.50.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.